SANOFI news, videos and press releases - Page 6
For more news please use our advanced search feature.
SANOFI - More news...
SANOFI - More news...
- Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes
- Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
- European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
- New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia
- Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
- Sanofi provides update on venglustat clinical program
- Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
- Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
- Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
- Sanofi: Information concerning the total number of voting rights and shares - March 2021
- Annual General Meeting of April 30, 2021
- Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
- Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
- Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
- FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
- Sanofi: Information concerning the total number of voting rights and shares - February 2021
- Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
- FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
- FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
- Sanofi: Information concerning the total number of voting rights and shares - January 2021
- FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
- Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
- Sanofi: Information concerning the total number of voting rights and shares - November 2020
- Availability of the Q4 2020 Memorandum for modelling purposes
- Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030
- Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
- Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities
- Sanofi: Information concerning the total number of voting rights and shares - October 2020
- Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
- European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
